Envision Pharma Group Appoints Industry Leader Tino Quintero as General Manager/VP of Market Access & Customer Insights

PHILADELPHIA, PA / ACCESSWIRE / May 1, 2023 / Envision Pharma Group (Envision) has appointed Tino Quintero to the role of General Manager/VP of Market Access & Customer Insights.

Tino will be responsible for collectively driving Envision’s capability building, client and business development, client servicing, and project execution, as well as staff development and mentorship for the Market Access & Customer Insights teams.

Meg Heim, CEO of Envision Pharma Group, shares, “I am so excited to welcome Tino to the Envision team as General Manager/VP of Market Access & Customer Insights. Tino’s depth of expertise and proven leadership capabilities in market access will drive Envision’s market access strategy as we continue to solidify our leadership and proficiency in the value and access and data analytics space. Tino will further support the acceleration of our business expansion, mission, and commitment to our vision as a technology-enabled partner to the life sciences industry.”

Tino has over 25 years of demonstrated success as a biopharma and life sciences executive. He possesses broad experience in global commercial strategy, market and value access, and business development at Sarepta Therapeutics, Gilead, Vertex, AbbVie, and Syneos. He has been instrumental in the launch and commercialization of numerous products in various therapeutic areas, including cell and gene therapy, rare diseases, oncology, and infectious and autoimmune diseases. He has a consistent and proven track record of success in building, leading, and executing corporate goals.

Tino joins Envision from The Q Group, where, as a founder, he advised executive leaders on critical operational and strategic areas for cell and gene therapy, mental health, and healthcare software companies. Prior to this, he was Chief Commercial Officer at Locus Biosciences where he led commercial strategy for the company’s early-stage pipeline assets, human resources, and strategic partnerships. Tino developed a go-to-market plan to secure Series B fundraising, corporate strategic leadership, and management of alliance partnerships.

Tino adds, “I am very fortunate to join the Envision Pharma Group team during this exciting time of growth. We are leveraging data, technology, and our teams’ experience to address customers’ needs and improve outcomes. I look forward to accelerating our current business while expanding into new markets and engaging new customers.”

About Envision Pharma Group

Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 18 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at www.envisionpharmagroup.com.

Contact Information:

Colleen Carter
Associate Director, Communications, Office of the CEO
colleen.carter@envisionpharma.com
1 (508) 505 8856

SOURCE: Envision Pharma Group

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Norfolk Southern Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – NSC

NEW YORK, April 30, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Norfolk Southern Corporation (NYSE: NSC) between October 28, 2020 and March 3, 2023, both dates inclusive (the “Class Period”), of the important May 15, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Norfolk Southern securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Norfolk Southern class action, go to https://rosenlegal.com/submit-form/?case_id=12322 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 15, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: During the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company’s Precision Scheduled Railroading (“PSR”), including its use of longer, heavier trains staffed by fewer personnel, had led to the Company suffering increased train derailments and a materially increased risk of future derailments; (2) the Company’s PSR, including its use of longer, heavier trains staffed by fewer personnel, was part of a culture of increased risk-taking at the expense of reasonable safety precautions due to the Company’s near-term focus solely on profits; (3) the Company’s PSR, including its use of longer, heavier trains staffed by fewer personnel, rendered the Company more vulnerable to train derailments and train derailments with potentially more severe human, financial, legal, and environmental consequences; (4) the Company’s capital spending and replacement programs were designed to prioritize profits over the Company’s ability to provide safe, efficient, and reliable rail transportation services; (5) the Company’s lobbying efforts had undermined the Company’s ability to provide safe, efficient, and reliable rail transportation services; (6) the Company’s commitment to reducing operating expenses as part of its PSR goals undermined worker safety and the Company’s purported “commitment to an injury free workplace” because the Company’s PSR plan prioritized reducing expenses through fewer personnel, longer trains, and less spending on safety training, technology, and equipment such as hot bearing wayside detectors (a/k/a “hotboxes”) and acoustic sensors; (7) the Company’s rail services were, as a result of its adoption of PSR principles, more susceptible to accidents that could cause serious economic and bodily harm to the Company, the Company’s workers, the Company’s customers, third parties, and the environment; (8) the Company had failed to put in place responsive practices and procedures to minimize the threat to communities in the event that these communities suffered the derailment of a Norfolk Southern train carrying hazardous and toxic materials; and (9) as a result, defendants’ Class Period statements detailed above regarding the safety of Norfolk Southern’s operations were materially false and/or misleading.

To join the Norfolk Southern class action, go to https://rosenlegal.com/submit-form/?case_id=12322 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8828189

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Fox Corporation Investors to Inquire About Class Action Investigation – FOX, FOXA

NEW YORK, April 30, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Fox Corporation (NASDAQ: FOX, FOXA) resulting from allegations that FOX may have issued materially misleading business information to the investing public. The prospective class includes those who purchased FOX call options and/or sold put options.

SO WHAT: If you purchased FOX securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=13327 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: In the wake of the 2020 U.S. Presidential Election, Dominion Voting Systems sued FOX for defamation. Dominion’s lawsuit alleges that FOX defamed Dominion’s business by endorsing, repeating or broadcasting a series of “verifiably false yet devastating lies about Dominion.” Dominion claims that various statements that were made on FOX News, including that Dominion committed election fraud by rigging the 2020 election, that Dominion’s software and algorithms manipulated vote counts in the 2020 election, that Dominion was founded for the purpose of rigging elections, and that Dominion paid kickbacks to government officials who used its machines, were defamatory and false. Dominion and Fox eventually agreed to settle the case for $787 million.

Beginning in February 2023, specific details emerged of internal discussions at FOX in the wake of the 2020 election, revealing that FOX’s senior leaders understood that claims to the effect that Dominion and other entities had rigged the 2020 election were false. As a consequence, FOX faces significant potential legal liability.

As a result of ongoing revelations about FOX’s legal exposure in the Dominion lawsuit, FOX’s Class A stock has declined from a closing price of $37.03 on February 17, 2023 to a closing price of $32.52 on March 15, 2023, a 12% decline. FOX’s Class B stock has declined from a closing price of $34.22 on February 17, 2023 to a closing price of $29.83 on March 15, 2023, a 12% decline.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8828165

Deputy Director General of Passports Inspects Work Progress at Jeddah Islamic Port Passports

Major General Dr. Saleh bin Saad Al-Murabba, Deputy Director General of the General Directorate of Passports, inspected the passports office at Jeddah Islamic Port and was briefed on the progress of entry procedures for citizens and nationals of brotherly and friendly countries arriving from Sudan.

During his visit, Major General Al-Murabba affirmed that the General Directorate of Passports has provided all necessary facilities and addressed all issues related to non-Saudi nationals who did not have entry visas or passports. The Directorate has also coordinated with their respective embassies and representations to complete the procedures for their return to their countries throughout the day.

This effort is part of the Directorate’s ongoing commitment to serving citizens and other nationals in coordination with partner agencies. The Directorate supports passport platforms with human and technical resources to expedite the completion of entry and exit procedures during evacuations

Source: Saudi Press Agency

Red Sea Global Launches Akun, a New Adventure Sports Company for the Kingdom

Red Sea Global (RSG), the developer behind the world’s most ambitious regenerative tourism destinations, the Red Sea and Amaala, has launched Akun, a new adventure sports brand that creates authentic and unique experiences for guests at RSG destinations. Akun operates in line with the responsible ethos of the group. Akun comes from Arabic meaning “to be”. It is deeply connected to the ambition of empowering guests to find their way. The brand reflects a mission to encourage people to live meaningfully, where every day is different.

“Akun will operate and manage adventure and sports experiences at RSG destinations, including gravel, mountain, fat tire and electric biking, plus trail running and hiking through diverse natural trails. Guests can choose from climbing, scrambling, and a wide selection of thrilling action sports for both beginners and athletes. Akun will also be closely connected to the local communities in each destination, working to develop conservation and cultural trails, and telling the incredible stories of these ancient lands. Akun’s formation comes after the developer’s transformation into Red Sea Global last year, which came with an ambition to establish a series of RSG-owned subsidiary businesses to support the evolution of its developments. WAMA and Galaxea were the first two subsidiary businesses to be announced back in February,” said John Pagano, Group CEO of Red Sea Global.

He added: “Combined with WAMA and Galaxea, our water sports and diving brands, we can now offer a full trio package of sporting experiences ahead of our first guests arriving at the Red Sea this year. Aligning with these brands and our broader company vision, Akun will operate with sustainability at its core and in line with our regenerative ambitions to protect and enhance the local environment. WAMA is responsible for offering invigorating water sport adventures, from stand-up paddleboarding through the destination’s mangrove forests, to sailing the Red Sea’s soft swells, while Galaxea will offer diving experiences that let guests explore the rich marine life below the water.”

Akun has already signed two initial partnership deals with operators Bungy New Zealand and Air Sports Group, which will both assess the enormous capacity for adventure tourism at RSG destinations. Air Sports Group will carry out a 13-week on-site technical assessment to ascertain the air sports potential at both Amaala and the Red Sea, with sports including skydiving, paragliding, paramotoring, and hot air ballooning. Bungy New Zealand will focus on developing the overall adventure tourism plan and concept designs for individual guest experiences.

“Through such partnerships with leading international experts, we are confident that we can successfully unlock the potential of our land, sea and skies, welcoming guests to find their way in this new adventure playground,” added Rosanna Chopra, Executive Director-Destination Development at Red Sea Global.

Source: Saudi Press Agency

Saudi Arabia Hosts 1st Meeting of Arab Authorities Controlling Medicines

The Kingdom of Saudi Arabia, represented by the Saudi Food and Drug Authority (SFDA), hosted the 1st Meeting of Arab Authorities Controlling Medicines today at the authority’s headquarters in Riyadh.

This meeting comes in implementation of Resolution No. (11) of the Council of Arab Ministers of Health in its (56th) regular session for 2022, as the Kingdom of Saudi Arabia welcomed at that time to host the aforementioned meeting, which is the first of its kind at the Arab level.

The objective of the meeting was to enhance Arab integration in the field of medicines control and legislation and to promote the exchange of expertise and best practices among Arab medicines control bodies and authorities.

Several topics were discussed at the meeting, including the registration procedures for pharmaceutical preparations, monitoring procedures for their safety, efficacy, and quality after marketing, and the role of medicines control laboratories in Arab countries.

Dr. Hisham bin Saad Aljadhey, CEO of the SFDA, emphasized that coordination and alignment with legal and regulatory requirements for medicines are key to facilitating the registration and availability of pharmaceutical products and lowering their cost, which in turn promotes access to these products for patients.

During the Kingdom’s presidency of the meeting, Dr. Aljadhey highlighted the importance of Arab integration in the field of medicines and encouraged Arab countries to hold such meetings regularly at the level of Arab bodies and authorities concerned with medicines control and registration, as well as specialized workshops to promote communication and coordination from the supervisory side.

It is noteworthy that the Technical Committee for Arab Medicines held a meeting on the sidelines of this event to monitor the implementation of Resolution No. (17) issued by the regular session (58) of the Council of Arab Ministers of Health in March 2023.

Representatives from the League of Arab States, the Hashemite Kingdom of Jordan, the United Arab Emirates, the Kingdom of Bahrain, the Republic of Tunisia, the People’s Democratic Republic of Algeria, the Republic of Djibouti, the Kingdom of Saudi Arabia, the Federal Republic of Somalia, the Republic of Iraq, the Sultanate of Oman, the State of Palestine, the State of Qatar, the United Republic of Comoros, the State of Kuwait, the Lebanese Republic, the Arab Republic of Egypt, the Kingdom of Morocco, and the Republic of Yemen participated in the meeting

Source: Saudi Press Agency